MX2023005027A - Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. - Google Patents
Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados.Info
- Publication number
- MX2023005027A MX2023005027A MX2023005027A MX2023005027A MX2023005027A MX 2023005027 A MX2023005027 A MX 2023005027A MX 2023005027 A MX2023005027 A MX 2023005027A MX 2023005027 A MX2023005027 A MX 2023005027A MX 2023005027 A MX2023005027 A MX 2023005027A
- Authority
- MX
- Mexico
- Prior art keywords
- hair loss
- deuterated
- regimens
- treatment
- loss disorders
- Prior art date
Links
- 201000004384 Alopecia Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000024963 hair loss Diseases 0.000 title abstract 2
- 230000003676 hair loss Effects 0.000 title abstract 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 abstract 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 abstract 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 abstract 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un método de tratamiento en un sujeto con trastornos de pérdida de cabello que se tratan de manera beneficiosa mediante la administración de un inhibidor de JAK1 y/o JAK2. El método comprende administrar al sujeto una cantidad eficaz del Compuesto (I): o una sal farmacéuticamente aceptable de este. (ver Fórmula) Compuesto (I).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063106790P | 2020-10-28 | 2020-10-28 | |
| US202163155637P | 2021-03-02 | 2021-03-02 | |
| PCT/US2021/057123 WO2022094133A1 (en) | 2020-10-28 | 2021-10-28 | Regimens for the treatment of hair loss disorders with deuterated jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005027A true MX2023005027A (es) | 2023-07-31 |
Family
ID=78725692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005027A MX2023005027A (es) | 2020-10-28 | 2021-10-28 | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230390292A1 (es) |
| EP (1) | EP4236956A1 (es) |
| JP (1) | JP2023553253A (es) |
| KR (1) | KR20230093504A (es) |
| AU (1) | AU2021372512A1 (es) |
| CA (1) | CA3196551A1 (es) |
| CL (1) | CL2023001201A1 (es) |
| CO (1) | CO2023006808A2 (es) |
| DO (1) | DOP2023000085A (es) |
| IL (1) | IL302401A (es) |
| MX (1) | MX2023005027A (es) |
| PE (1) | PE20231945A1 (es) |
| WO (1) | WO2022094133A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023265574A1 (en) * | 2022-05-04 | 2024-12-12 | Sun Pharmaceutical Industries, Inc. | Dosage regimens for treatment with deuterated jak inhibitors |
| US12364699B2 (en) * | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
| US12247034B1 (en) * | 2024-04-19 | 2025-03-11 | Sun Pharmaceutical Industries, Inc. | Crystalline form of deuruxolitinib phosphate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| CA2444116C (en) | 2001-05-03 | 2009-01-20 | F. Hoffmann-La Roche Ag | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| KR20070083839A (ko) | 2004-09-29 | 2007-08-24 | 코디스 코포레이션 | 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태 |
| EP3219705B1 (en) | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| PT3882249T (pt) | 2012-06-15 | 2025-08-06 | Sun Pharmaceutical Ind Inc | Derivados deuterados de ruxolitinib |
| DK3452039T3 (da) * | 2016-05-04 | 2024-10-07 | Sun Pharmaceutical Ind Inc | Behandling af hårtabslidelser med deutererede jakhæmmere |
| WO2020163653A1 (en) | 2019-02-06 | 2020-08-13 | Concert Pharmaceuticals, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| AU2022328272A1 (en) * | 2021-08-11 | 2024-02-22 | Sun Pharmaceutical Industries, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| US12364699B2 (en) * | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
-
2021
- 2021-10-28 MX MX2023005027A patent/MX2023005027A/es unknown
- 2021-10-28 PE PE2023001507A patent/PE20231945A1/es unknown
- 2021-10-28 WO PCT/US2021/057123 patent/WO2022094133A1/en not_active Ceased
- 2021-10-28 US US18/033,730 patent/US20230390292A1/en active Pending
- 2021-10-28 IL IL302401A patent/IL302401A/en unknown
- 2021-10-28 JP JP2023526173A patent/JP2023553253A/ja active Pending
- 2021-10-28 AU AU2021372512A patent/AU2021372512A1/en active Pending
- 2021-10-28 KR KR1020237017998A patent/KR20230093504A/ko active Pending
- 2021-10-28 EP EP21811647.3A patent/EP4236956A1/en active Pending
- 2021-10-28 CA CA3196551A patent/CA3196551A1/en active Pending
-
2023
- 2023-04-26 CL CL2023001201A patent/CL2023001201A1/es unknown
- 2023-04-28 DO DO2023000085A patent/DOP2023000085A/es unknown
- 2023-05-25 CO CONC2023/0006808A patent/CO2023006808A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL302401A (en) | 2023-06-01 |
| JP2023553253A (ja) | 2023-12-21 |
| CL2023001201A1 (es) | 2023-11-17 |
| WO2022094133A1 (en) | 2022-05-05 |
| WO2022094133A9 (en) | 2023-05-19 |
| CA3196551A1 (en) | 2022-05-05 |
| US20230390292A1 (en) | 2023-12-07 |
| DOP2023000085A (es) | 2023-07-31 |
| CO2023006808A2 (es) | 2023-09-08 |
| KR20230093504A (ko) | 2023-06-27 |
| PE20231945A1 (es) | 2023-12-05 |
| EP4236956A1 (en) | 2023-09-06 |
| AU2021372512A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005027A (es) | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. | |
| EP4424367A3 (en) | Treatment of hair loss disorders with deuterated jak inhibitors | |
| MX2024000820A (es) | Compuestos para la inhibicion de proteinas que contienen el dominio de pirina de la familia nlr 3 (nlrp3) y usos de estos. | |
| MX2021011928A (es) | Composiciones y metodos para el tratamiento de enfermedades o trastornos asociados con kras. | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| PH12021551402A1 (en) | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors | |
| MX2020002646A (es) | Inhibidores de enpp1 y su uso para el tratamiento del cancer. | |
| ZA202206485B (en) | Use of bi853520 in cancer treatment | |
| MX2023010728A (es) | Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor. | |
| PH12022553501A1 (en) | Alk2 inhibitors for the treatment of anemia | |
| MX2024014121A (es) | Metodos y composiciones para el tratamiento del exceso de glucocorticoides | |
| MX2024006678A (es) | Inhibidor de cdk4 para el tratamiento del cancer. | |
| MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. | |
| MX2022015146A (es) | Tratamiento de la artritis reumatoide. | |
| PH12023550780A1 (en) | Line-1 inhibitors to treat disease | |
| PH12021551975A1 (en) | Use of vibegron to treat overactive bladder | |
| MX2024013641A (es) | Regimenes de dosificacion para el tratamiento con inhibidores deuterados de jak | |
| PH12021553098A1 (en) | Treatment for synucleinopathies | |
| MX2025001316A (es) | Tratamiento de la urticaria con inhibidores de la cinasa de janus (jak) | |
| MX2023002422A (es) | Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson. | |
| MX2025003908A (es) | Compuesto inhibidor de parg | |
| WO2024026458A3 (en) | Use of glycogen metabolism inhibitors for the treatment of cancer | |
| MX2024014166A (es) | Inhibidores de ripk1 y metodos de uso | |
| EA201892360A1 (ru) | Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak | |
| MX2025010790A (es) | Inhibidores de la vía cinasa janus 1 (jak1) para el tratamiento del asma |